# Rituximab for Prevention of Rejection After Renal Transplantation

> **NCT00565331** · PHASE2,PHASE3 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 280 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00565331
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2013-12
- **Final completion:** 2015-06
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2015-11-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00565331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00565331, "Rituximab for Prevention of Rejection After Renal Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00565331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*